



Longfellow Welcomes Envisia Therapeutics to RTP's Exchange Place / Imperial Center

Major Renovations Enhance Life Sciences Destination

(Research Triangle Park, NC) -- September 26, 2016 -- [Envisia Therapeutics](#) will join [Longfellow Real Estate Partner](#)'s tenant roster of cutting edge life sciences companies at the Imperial Center Office Park in RTP.

Envisia Therapeutics discovers and develops novel therapies to address significant unmet medical needs in ophthalmology. The company will occupy 12,595 square feet of office and lab space focused primarily on research and development in Imperial Center's Exchange Place property.

In 2014, Longfellow purchased Royal Center and Exchange Place (totaling 180,000 sq ft within Imperial Center Office Park). It has since completed a redevelopment of Exchange Place including upgraded exterior and parking, new landscaping and conversion of flex space to state-of-the-art lab space.

Three years ago, Envisia Therapeutics spun out of Liquidia Technologies, a member of Longfellow's Keystone Technology Park community. The company now employs 30 people, primarily in RTP. This evolution demonstrates Longfellow's commitment to providing exceptional office and lab space to companies at every stage of their development.

Sue Back with Foundry Commercial represented Envisia Therapeutics while Neill Sherron represented Longfellow in the lease transaction.

Quote from Longfellow

"Longfellow is successfully developing, managing and leasing the largest science and technology portfolio in the Triangle, supporting the wants and needs of mature and expanding life science and technology companies. We're thrilled to welcome Envisia Therapeutics and their team to the Longfellow community and look forward to helping them as they continue to innovate and grow." - Jessica Furman Brock, Managing Director, Longfellow Real Estate Partners

Quote from Envisia

“Envisia continues to make great strides in its effort to advance novel therapeutics for the leading causes of vision loss and with that progress our needs often change. Since the beginning, Longfellow has been a valued partner in ensuring that we stay ahead of that growth with state-of-the-art R&D facilities and other workspaces that foster comfort, convenience and productivity. We are very pleased with our selection and experience.” – Eric Linsley, Chief Financial Officer at Envisia

Longfellow's New Durham.ID Buildings

In July, Longfellow unveiled designs for the construction of two new mixed-use buildings and an adjoining parking deck at The Durham Innovation District ([Durham.ID](#)), a 15-acre research hub and live-work-play campus that connects dynamic neighborhoods on the west side of the Bull City's thriving downtown.

The buildings – focused primarily on office and technology use, but also including retail and restaurants – will be located on Morris Street between Hunt and Roney in what is currently a large parking lot. Each building – known as North and South – will reach seven stories, together totaling nearly 350,000 square feet. Duke Clinical Research Institute (DCRI) has signed a lease to occupy all of the office space in the South Building.

Renderings are available [here](#). Construction is slated to begin in Q3 2016 with completion expected in the Spring of 2018.

Multi-Media

- Video: [Durham Innovation District \(Durham.ID\)](#)
- Renderings of Longfellow's North and South Buildings: [Available here](#)

Press Contacts (not for publication)

- Longfellow Media Contacts: Billy Warden (919.412.0630) or Greg Behr (919.272.5621)
- Envisia Therapeutics Media Contact: Michael Parks, 484.356.7105, michael@pitch360inc.com
- Envisia Therapeutics Investor Contact: Jenny Kobin, 919-423-4799, Jenny.Kobin@IRAdvisory.com

About Longfellow Real Estate Partners

[Longfellow Real Estate Partners](#) serves the unique demands of science and technology companies and focuses on the most innovative cluster locations in the US. The firm acquires and develops facilities in strategic locations and builds long-term relationships with research-centric organizations including life science companies, universities, medical centers and research institutes. The principals of Longfellow have developed more than 3.5 million square feet of laboratory and high tech space over their careers including numerous high profile projects on the East Coast. The Company's institutional capabilities and entrepreneurial vision enables Longfellow to deliver high quality laboratories and innovation space while satisfying each tenant's unique requirements.

About Envisia Therapeutics

Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

###